Johnson & Johnson (JNJ) is trading at $229.02, marking a price change of $3.68 (1.63%) from the previous close of $225.34. The trading volume is $2.54 million, representing a 30.42% increase relative to the average.
JNJ's latest quarterly earnings report on Monday, April 13th, surpassed expectations with a consensus estimate EPS of 2.67.
With a forward dividend yield of 2.27%, JNJ distributed $1.3 per share MRQ and $5.2 TTM, showcasing stability and investor value.
JNJ exhibited strong financial health with a free cash flow of $1.47 billion, operating cash flow of $2.51 billion, and a net cash increase of $1.98 billion.
Revenue stood at $24 billion, with a gross profit of $17.20 billion. JNJ reported a net income of $5.24 billion and an EPS of $2.14, reflecting solid profitability.
Key ratios include a gross profit margin of 71.49%, net profit margin of 21.76%, and a price-earnings ratio of 28.54, indicating stable performance and investor confidence.
JNJ's balance sheet reveals total assets of $200.89 billion, total liabilities of $119.71 billion, and net debt of $-4.23 billion, highlighting a strong financial position.
This real-time financial report underscores JNJ's positive performance, robust financial metrics, and strategic positioning in the market.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.